PPARδ and PPARγ pharmacological and genetic enhancement attenuated hepatic steatosis by inducing autophagy dependent hepatic lipolysis and ß-oxidation in mouse livers and primary mouse hepatocytes (Tong et al., 2019) and improving insulin sensitivity (Heikkinen et al., 2007). This evidence concerns the gene INS and fatty liver disease.